1996;61:1793 6. 1189. Bae KS, Park HC, Kang BS, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary artery disease and diabetic nephropathy: a single center experience. Korean J Intern Med. 2007;22:139 46. 1190. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J. 2005; 149:512 9. 1191. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circu- lation. 2004;110:1890 5. 1192. Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insuf- ficiency. Kidney Int. 2001;60:292 9. 1193. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104:1647 53. 1194. Reddan DN, Szczech LA, Tuttle RH, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically sig- nificant coronary artery disease. J Am Soc Nephrol. 2003;14:2373 80. 1195. Tabib A, Leroux C, Mornex JF, et al. Accelerated coronary atheroscle- rosis and arteriosclerosis in young human-immunodeficiency- viruspositive patients. Coron Artery Dis. 2000;11:41 6. 1196. Mehta NJ, Khan IA. HIV-associated coronary artery disease. Angiology. 2003;54:269 75. 1197. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med. 2003;163:457 60. 1198. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723 35. 1199. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978 82. 1200. Dube MP, Stein JH, Aberg JA, et al. 